RA Capital Management’s Relmada Therapeutics RLMD Stock Holding History

RA Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.5M	Buy	+2,947,369	New	+$13.9M	0.22%	58
2022 Q4	–	Sell	-2,000,000	Closed	-$74M	–	79
2022 Q3	$74M	Hold	2,000,000	–	–	1.58%	18
2022 Q2	$38M	Hold	2,000,000	–	–	1.01%	32
2022 Q1	$54M	Hold	2,000,000	–	–	1.18%	25
2021 Q4	$45.1M	Buy	+2,000,000	New	+$44.5M	0.79%	37
2020 Q4	–	Sell	-781,290	Closed	-$29.4M	–	86
2020 Q3	$29.4M	Sell	781,290 -70,617	-8%	-$2.73M	0.54%	43
2020 Q2	$38.1M	Sell	851,907 -528,081	-38%	-$22.3M	0.74%	33
2020 Q1	$47.1M	Buy	1,379,988 +618,322	+81%	+$24.9M	1.49%	24
2019 Q4	$29.7M	Buy	+761,666	New	+$23.1M	0.9%	24

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RA Capital Management's RLMD Position: Q1 2026 in Review

RA Capital Management opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 2,947,369 shares worth $20.5M. The stake represents 0.22% of the portfolio and ranks #58 among its holdings. This is a return to the name: RA Capital Management previously reported a position in RLMD as recently as Q3 2022.

RA Capital Management first reported a position in RLMD in Q4 2019 and has held it in 9 quarters since. The position peaked at $74M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

RA Capital Management held 2,947,369 shares of Relmada Therapeutics worth $20.5M as of Q1 2026.
Relmada Therapeutics was a new RA Capital Management position in Q1 2026.
Relmada Therapeutics made up 0.22% of RA Capital Management's portfolio in Q1 2026, its #58 holding.
RA Capital Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 9 quarters since.
RA Capital Management's Relmada Therapeutics position peaked at $74M in Q3 2022.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.